On October 28, 2026, Anthropic announced a deep collaboration between its life sciences team and six institutions, including Bristol-Myers Squibb and Generate Biomedicines, to launch an autonomous drug discovery project. The initial focus is on a rare pediatric muscular atrophy, with Claude handling the majority of scientific and operational tasks. This collaboration aims to leverage AI technology to accelerate drug development for rare diseases, reduce research and development costs, improve efficiency, and enable early data sharing to advance global rare disease research.
